

Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup. P512

Marco Rubatto^{1*}, Paolo Fava^{1*}, Ignazio Stanganelli², Simone Ribero¹, Jacopo Pigozzo³, Anna Maria Di Giacomo⁴, Laura Ridolfi⁵, Maria Chiara Tronconi⁶, Claudia Trojaniello⁷, Melissa Bersanelli⁸, Mattia Garutti⁹, Alice Indini¹⁰, Ivana De Risi¹¹, Michele De Tursi¹², Barbara Merelli¹³, Francesca Morgese¹⁴, Marcella Occelli¹⁵, Gian Carlo Antonini Cappellini¹⁶, Stefano Poletto¹⁷, Dahlia Fedele¹⁸, Sonia Brugnara¹⁹, Michela Frisinghelli¹⁹, Luigi Formisano²⁰, Raffele Conca²¹, Marco Tucci²², Virginia Ferraresi²³, Sabino Strippoli¹¹, Michele Guida^{11#}, Pietro Quaglino^{1#}.

* This authors contributed equally # This authors share senior authorship

¹Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy. (Correspondig author: <u>rubattomarco@gmail.com 346 4191141</u>) ²Skin Cancer Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.⁴Center for Immuno Oncology, University Hospital of Siena, Siena, Italy.⁵Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.⁸Medical Oncology Unit, Humanitas Clinical and Research Center, Humanitas Clinical Oncology Unit, Humanitas Clinical and Research Center, Humanitas Clinical Oncology Unit, Humanitas Clinical and Research Center, Humanitas Clinical and Research Center, Humanitas Clinical Oncology Unit, Humanitas Clinical and Research Center, Humanitas Clinical A Italy.⁹CRO Aviano National Cancer Institute IRCCS, 33081 Aviano, Italy.¹⁰Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.¹³Unit of Medical Oncology, Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Piazza OMS 1, 24100, Bergamo, Italy.¹⁶UOC Oncologia Interpresidio, Ospedali Riuniti Di Ancona, Italy.¹⁵Department of Medicine, Clinical Oncologica, Università Politecnica delle Marche, AOU Ospedali Riuniti Di Ancona, Italy.¹⁶UOC Oncologia Interpresidio, Ospedale Sandro Pertini, ASL Roma2.17 Istituto di Candiolo, FPO - IRCCS - Candiolo, Italy.¹⁸ Skin Cancer Unit, Department of Medical Oncology, Maggiore Hospital, Trento, Italy.²⁰ Department of Chical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²¹ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²² Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²² Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²³ Division of Medical Oncology, Santa Chiara Hospital, Trento, Italy.²⁴ Division of Medical Vulture , Italy.²²Department of Biomedical Sciences and Clinical Oncology, University of Bari 'Aldo Moro', Section of Internal Medicine and Oncology, P.za Giulio Cesare, 11 - 70124 BARI, Italy.²³Department of Cancer Medicine, Istituto Regina Elena, Rome, Italy.

Background


Immunotherapy has improved the survival of patients with stage IV melanoma. In responding subjects, clinical benefits may be long-lasting and persist even after treatment discontinuation. However, a few data are available on clinical outcomes of patients that discontinued anti-PD1 immunotherapy in a real-life setting.

Objective

The aim of this study was to evaluate the progression of free survival (PFS) in patients with metastatic melanoma who interrupted anti PD-1 treatment in complete response (CR) or due to limiting toxicity.

Materials and Methods

This multicenter study included 328 patients with advanced melanoma, at 23 Italian medical centers belonging to IMI (Italian Melanoma Intergroup). The study investigated the relapse risk in 237 patients who stopped anti-PD1 therapy due to complete response, treatmentrelated toxicity or by their own choice after a long period of treatment. Patients in disease progression at therapy interruption were excluded during follow-up. Clinical and biological factors associated with recurrence were studied.



Results

- The median age of patients was 68.9 years (standard deviation: 13; range 33-95). The median time on treatment was 33 months (standard deviation: 18,7; range 1-98). Out of 237 patients, 128 patients (54%) interrupted anti-PD1 for CR, 74 patients (31.2%) for adverse effects (36 patients in CR, 25 patients in partial response (PR), 9 patients in stable disease (SD) and 2 patients in disease progression (PD)) and 35 patients (14.8%) by their own choice (12 patients in CR, 17 patients in PR and 6 patients in SD). After a median follow up of 21 months (range 1-81) after treatment discontinuation, 85.7% of patients remain disease free. 34 patients (14.3%) developed a relapse after a median time of 12 months (range 1-35): 10 patients (29.4%) after discontinuation for CR, 17 patients (50%) after discontinuation for treatment-related toxicity (7 in CR, 5 in PR, 5 in SD) and 7 patients (20.6%) after discontinuation due to the patient's decision (2 in CR, 4 in PR, 1 in SD). Only 7.8% of patients who interrupted for CR (10/128), 23% of patients who interrupted for limiting toxicity (17/74) and 20% of patients who interrupted by their own choice (7/35) developed recurrence.
- Regarding patients who discontinued therapy because of CR, we observed a statistically significant association between recurrence and site of primitive melanoma, particularly visceral/mucosal site (p=<0.05). Moreover, patient with a metastatic disease limited to the lung who obtained a CR were characterized by a lower number of relapses (p=<0.05).
- At last, we observed an association between site of primary melanoma – in particular unknown primary site - and discontinuation for treatmentrelated toxicity (p=<0.05).
- Sex, ECOG, LDH, mutation of BRAF and NRAS, Breslow's index, Clark's level, site and number of metastases, vitiligo were studied but did not demonstrate any association with relapse rate.

(Figure 2b)

